Myriad Modalities Advance Multiple Myeloma Paradigm

Ellie Leick
Published: Tuesday, Nov 26, 2019
Nina Shah, MD, an associate professor of medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center

Nina Shah, MD

Chimeric antigen receptor (CAR) T-cell therapy, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates (ADCs) have all shown encouraging activity in patients with multiple myeloma, although investigators are still exploring the therapies to improve outcomes, explained Nina Shah, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication